Table 3.

Clinical characteristics of patients with AML whose samples were used for in vivo experiments

Patient No.OxPhosi sensitivityDiagnosisMutation status
27 Sensitive AML FLT3-ITD, CEPBA, IDH1, NPM1, NRAS 
28 Sensitive AML FLT3-ITD, DNMT3A, IDH1, KIT, NPM1 
29 Sensitive AMML FLT3-ITD, IDH1, NPM1 
30 Resistant AML FLT3-ITD, DNMT3A, NPM1, TP53 
31 Resistant AML FLT3-ITD, DNMT3A, IDH2, NPM1 
32 Resistant AML FLT3-ITD, DNMT3A, IDH1, NPM1 
33 Resistant AML FLT3-ITD, DNMT3A, EGFR, IDH1, NPM1, TET2 
Patient No.OxPhosi sensitivityDiagnosisMutation status
27 Sensitive AML FLT3-ITD, CEPBA, IDH1, NPM1, NRAS 
28 Sensitive AML FLT3-ITD, DNMT3A, IDH1, KIT, NPM1 
29 Sensitive AMML FLT3-ITD, IDH1, NPM1 
30 Resistant AML FLT3-ITD, DNMT3A, NPM1, TP53 
31 Resistant AML FLT3-ITD, DNMT3A, IDH2, NPM1 
32 Resistant AML FLT3-ITD, DNMT3A, IDH1, NPM1 
33 Resistant AML FLT3-ITD, DNMT3A, EGFR, IDH1, NPM1, TET2 
[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal